Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company has received final approval from the United States (U.S.) Food and Drug Administration (FDA) for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution in the 0.5 mg/3 mg strength.

Watson's Ipratropium Bromide and Albuterol Sulfate product is the generic equivalent to Dey, L.P.'s DuoNeb®, which is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) in patients requiring more than one bronchodilator. Watson intends to launch its Ipratropium Bromide and Albuterol Sulfate product immediately.

Watson Pharmaceuticals, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.